Quidel Corporation (QDEL)

Currency in USD
26.60
+1.06(+4.15%)
Closed·
After Hours
26.600.00(0.00%)
·
QDEL Scorecard
Full Analysis
Operates with a significant debt burden
Earnings results expected in 12 days
Fair Value
Day's Range
25.8626.97
52 wk Range
23.7749.45
Key Statistics
Prev. Close
25.54
Open
26.15
Day's Range
25.86-26.97
52 wk Range
23.77-49.45
Volume
1.74M
Average Volume (3m)
1.62M
1-Year Change
-27.99%
Book Value / Share
44.44
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QDEL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
47.14
Upside
+77.23%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Quidel Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Quidel Corporation Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Quidel Corporation SWOT Analysis


Financial Resilience
QuidelOrtho demonstrates strong Q2 2024 performance, with analysts projecting net income growth despite recent revenue challenges
Strategic Cost-Cutting
Explore the $100 million cost rationalization plan aimed at improving medium-term margins and enhancing QuidelOrtho's financial health
Savanna's Potential
Learn about the anticipated 2025 U.S. launch of Savanna, a key product expected to drive future revenue and market expansion for QuidelOrtho
Analyst Optimism
Delve into analyst perspectives, with price targets ranging from $38 to $64 and an average consensus recommendation of 2.38 on InvestingPro's scale
Read full SWOT analysis

Quidel Corporation Earnings Call Summary for Q1/2025

  • QuidelOrtho Q1 2025 adjusted EPS of $0.74 beat forecast by 21.3%, revenue slightly missed at $693 million
  • Stock surged 7.5% in aftermarket trading to $27.79, despite 42% YTD decline
  • FY2025 guidance: revenue $2.6-2.81 billion, adjusted EPS $2.07-2.57; focus on cost savings and operational efficiencies
  • Strong growth in molecular diagnostics and respiratory segments; 23% adjusted EBITDA margin achieved
  • Potential $30-40 million tariff impact in 2025; company plans strategic pricing and supply chain adjustments
Last Updated: 07/05/2025, 23:28
Read Full Transcript

Compare QDEL to Peers and Sector

Metrics to compare
QDEL
Peers
Sector
Relationship
P/E Ratio
−5.0x−2.0x−0.5x
PEG Ratio
−0.060.170.00
Price/Book
0.6x3.1x2.6x
Price / LTM Sales
0.7x4.0x3.2x
Upside (Analyst Target)
95.8%33.7%41.9%
Fair Value Upside
Unlock−6.0%4.3%Unlock

Analyst Ratings

5 Buy
2 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 47.14
(+77.23% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
0.74 / 0.61
Revenue / Forecast
693.00M / 694.43M
EPS Revisions
Last 90 days

QDEL Income Statement

People Also Watch

13.32
SRPT
-2.13%
20.63
GAP
-0.43%
29.42
CNC
+5.49%
30.80
YOU
+3.18%

FAQ

What Stock Exchange Does Quidel Trade On?

Quidel is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Quidel?

The stock symbol for Quidel is "QDEL."

What Is the Quidel Market Cap?

As of today, Quidel market cap is 1.80B.

What Is Quidel's Earnings Per Share (TTM)?

The Quidel EPS (TTM) is -5.33.

When Is the Next Quidel Earnings Date?

Quidel will release its next earnings report on 04 Aug 2025.

From a Technical Analysis Perspective, Is QDEL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Quidel Stock Split?

Quidel has split 0 times.

How Many Employees Does Quidel Have?

Quidel has 6600 employees.

What is the current trading status of Quidel (QDEL)?

As of 24 Jul 2025, Quidel (QDEL) is trading at a price of 26.60, with a previous close of 25.54. The stock has fluctuated within a day range of 25.86 to 26.97, while its 52-week range spans from 23.77 to 49.45.

What Is Quidel (QDEL) Price Target According to Analysts?

The average 12-month price target for Quidel is USD47.14286, with a high estimate of USD60 and a low estimate of USD27. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +77.23% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.